BE686324A - - Google Patents
Info
- Publication number
- BE686324A BE686324A BE686324DA BE686324A BE 686324 A BE686324 A BE 686324A BE 686324D A BE686324D A BE 686324DA BE 686324 A BE686324 A BE 686324A
- Authority
- BE
- Belgium
- Prior art keywords
- thiamphenicol
- following
- hydroxy
- compound
- treatment
- Prior art date
Links
- 238000011282 treatment Methods 0.000 claims description 13
- DHMQDGOQFOQNFH-UHFFFAOYSA-N Glycine Chemical compound NCC(O)=O DHMQDGOQFOQNFH-UHFFFAOYSA-N 0.000 claims description 12
- OTVAEFIXJLOWRX-NXEZZACHSA-N thiamphenicol Chemical compound CS(=O)(=O)C1=CC=C([C@@H](O)[C@@H](CO)NC(=O)C(Cl)Cl)C=C1 OTVAEFIXJLOWRX-NXEZZACHSA-N 0.000 claims description 11
- 229960003053 thiamphenicol Drugs 0.000 claims description 10
- 239000003814 drug Substances 0.000 claims description 8
- 238000000034 method Methods 0.000 claims description 8
- 230000008569 process Effects 0.000 claims description 8
- 230000001225 therapeutic effect Effects 0.000 claims description 8
- 239000000203 mixture Substances 0.000 claims description 7
- BCEQKAQCUWUNML-UHFFFAOYSA-N 4-hydroxybenzene-1,3-dicarboxylic acid Chemical compound OC(=O)C1=CC=C(O)C(C(O)=O)=C1 BCEQKAQCUWUNML-UHFFFAOYSA-N 0.000 claims description 6
- 239000004471 Glycine Substances 0.000 claims description 6
- 208000015181 infectious disease Diseases 0.000 claims description 5
- 230000002458 infectious effect Effects 0.000 claims description 5
- 229940102396 methyl bromide Drugs 0.000 claims description 5
- GZUXJHMPEANEGY-UHFFFAOYSA-N methyl bromide Substances BrC GZUXJHMPEANEGY-UHFFFAOYSA-N 0.000 claims description 5
- 150000001875 compounds Chemical class 0.000 claims description 4
- 159000000000 sodium salts Chemical class 0.000 claims description 4
- 239000002904 solvent Substances 0.000 claims description 2
- 229940125904 compound 1 Drugs 0.000 claims 2
- 239000002361 compost Substances 0.000 claims 1
- 239000000126 substance Substances 0.000 claims 1
- 239000000047 product Substances 0.000 description 11
- 230000003115 biocidal effect Effects 0.000 description 6
- 230000003110 anti-inflammatory effect Effects 0.000 description 5
- 230000000694 effects Effects 0.000 description 5
- 239000000243 solution Substances 0.000 description 5
- 206010037660 Pyrexia Diseases 0.000 description 3
- 241000700159 Rattus Species 0.000 description 3
- 238000006243 chemical reaction Methods 0.000 description 3
- 229940079593 drug Drugs 0.000 description 3
- 238000002360 preparation method Methods 0.000 description 3
- RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 description 2
- 241001465754 Metazoa Species 0.000 description 2
- 206010030113 Oedema Diseases 0.000 description 2
- 206010073329 Perineal injury Diseases 0.000 description 2
- 206010036423 Postpartum uterine subinvolution Diseases 0.000 description 2
- GUGOEEXESWIERI-UHFFFAOYSA-N Terfenadine Chemical compound C1=CC(C(C)(C)C)=CC=C1C(O)CCCN1CCC(C(O)(C=2C=CC=CC=2)C=2C=CC=CC=2)CC1 GUGOEEXESWIERI-UHFFFAOYSA-N 0.000 description 2
- 239000002253 acid Substances 0.000 description 2
- 230000001387 anti-histamine Effects 0.000 description 2
- 239000000739 antihistaminic agent Substances 0.000 description 2
- DDRJAANPRJIHGJ-UHFFFAOYSA-N creatinine Chemical compound CN1CC(=O)NC1=N DDRJAANPRJIHGJ-UHFFFAOYSA-N 0.000 description 2
- 239000012153 distilled water Substances 0.000 description 2
- 238000002474 experimental method Methods 0.000 description 2
- 238000000338 in vitro Methods 0.000 description 2
- 238000001727 in vivo Methods 0.000 description 2
- 230000008595 infiltration Effects 0.000 description 2
- 238000001764 infiltration Methods 0.000 description 2
- 230000002757 inflammatory effect Effects 0.000 description 2
- 238000007918 intramuscular administration Methods 0.000 description 2
- 230000003902 lesion Effects 0.000 description 2
- 239000002547 new drug Substances 0.000 description 2
- 230000002980 postoperative effect Effects 0.000 description 2
- 150000003839 salts Chemical class 0.000 description 2
- 230000028327 secretion Effects 0.000 description 2
- 238000011477 surgical intervention Methods 0.000 description 2
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 2
- 230000036642 wellbeing Effects 0.000 description 2
- FUFLCEKSBBHCMO-UHFFFAOYSA-N 11-dehydrocorticosterone Natural products O=C1CCC2(C)C3C(=O)CC(C)(C(CC4)C(=O)CO)C4C3CCC2=C1 FUFLCEKSBBHCMO-UHFFFAOYSA-N 0.000 description 1
- MFYSYFVPBJMHGN-ZPOLXVRWSA-N Cortisone Chemical compound O=C1CC[C@]2(C)[C@H]3C(=O)C[C@](C)([C@@](CC4)(O)C(=O)CO)[C@@H]4[C@@H]3CCC2=C1 MFYSYFVPBJMHGN-ZPOLXVRWSA-N 0.000 description 1
- MFYSYFVPBJMHGN-UHFFFAOYSA-N Cortisone Natural products O=C1CCC2(C)C3C(=O)CC(C)(C(CC4)(O)C(=O)CO)C4C3CCC2=C1 MFYSYFVPBJMHGN-UHFFFAOYSA-N 0.000 description 1
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 description 1
- 108010058846 Ovalbumin Proteins 0.000 description 1
- 206010060932 Postoperative adhesion Diseases 0.000 description 1
- 241000295644 Staphylococcaceae Species 0.000 description 1
- 102000003929 Transaminases Human genes 0.000 description 1
- 108090000340 Transaminases Proteins 0.000 description 1
- 208000027418 Wounds and injury Diseases 0.000 description 1
- 238000010521 absorption reaction Methods 0.000 description 1
- 230000004913 activation Effects 0.000 description 1
- 230000002921 anti-spasmodic effect Effects 0.000 description 1
- 229940124575 antispasmodic agent Drugs 0.000 description 1
- 239000007864 aqueous solution Substances 0.000 description 1
- 230000015556 catabolic process Effects 0.000 description 1
- 239000003795 chemical substances by application Substances 0.000 description 1
- 230000001684 chronic effect Effects 0.000 description 1
- 229960004544 cortisone Drugs 0.000 description 1
- 229940109239 creatinine Drugs 0.000 description 1
- 230000006378 damage Effects 0.000 description 1
- 238000006731 degradation reaction Methods 0.000 description 1
- 230000002349 favourable effect Effects 0.000 description 1
- 210000005002 female reproductive tract Anatomy 0.000 description 1
- 239000000706 filtrate Substances 0.000 description 1
- 238000001914 filtration Methods 0.000 description 1
- 238000004108 freeze drying Methods 0.000 description 1
- 239000003292 glue Substances 0.000 description 1
- 238000010562 histological examination Methods 0.000 description 1
- 238000002347 injection Methods 0.000 description 1
- 239000007924 injection Substances 0.000 description 1
- 208000014674 injury Diseases 0.000 description 1
- 230000003907 kidney function Effects 0.000 description 1
- 210000004185 liver Anatomy 0.000 description 1
- 230000003908 liver function Effects 0.000 description 1
- 230000010534 mechanism of action Effects 0.000 description 1
- 238000002844 melting Methods 0.000 description 1
- 230000008018 melting Effects 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- 231100000252 nontoxic Toxicity 0.000 description 1
- 230000003000 nontoxic effect Effects 0.000 description 1
- 210000000056 organ Anatomy 0.000 description 1
- 229940124641 pain reliever Drugs 0.000 description 1
- 210000004738 parenchymal cell Anatomy 0.000 description 1
- 210000004197 pelvis Anatomy 0.000 description 1
- 239000008196 pharmacological composition Substances 0.000 description 1
- 239000006187 pill Substances 0.000 description 1
- 239000002244 precipitate Substances 0.000 description 1
- 230000000750 progressive effect Effects 0.000 description 1
- 230000000069 prophylactic effect Effects 0.000 description 1
- 238000011321 prophylaxis Methods 0.000 description 1
- 230000009467 reduction Effects 0.000 description 1
- 229910052708 sodium Inorganic materials 0.000 description 1
- 239000011734 sodium Substances 0.000 description 1
- 238000001228 spectrum Methods 0.000 description 1
- 230000001954 sterilising effect Effects 0.000 description 1
- 238000001356 surgical procedure Methods 0.000 description 1
- 238000012360 testing method Methods 0.000 description 1
- 238000011287 therapeutic dose Methods 0.000 description 1
- 238000012795 verification Methods 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C317/00—Sulfones; Sulfoxides
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
- Agricultural Chemicals And Associated Chemicals (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| IT1970065 | 1965-09-02 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| BE686324A true BE686324A (cs) | 1967-02-15 |
Family
ID=11160486
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| BE686324D BE686324A (cs) | 1965-09-02 | 1966-09-01 |
Country Status (3)
| Country | Link |
|---|---|
| BE (1) | BE686324A (cs) |
| ES (1) | ES330699A1 (cs) |
| FR (1) | FR5830M (cs) |
-
1966
- 1966-08-19 FR FR73619A patent/FR5830M/fr not_active Expired
- 1966-08-29 ES ES0330699A patent/ES330699A1/es not_active Expired
- 1966-09-01 BE BE686324D patent/BE686324A/fr not_active IP Right Cessation
Also Published As
| Publication number | Publication date |
|---|---|
| ES330699A1 (es) | 1967-06-16 |
| FR5830M (cs) | 1968-02-26 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CA2024419C (fr) | Nouveaux sels de metaux bivalents de l'acide n,n-di(carboxymethyl) amino-2cyano-3carboxymethyl-4 carboxy-5 thiophene, leur procede de preparation et les compositions pharmaceutiques les renfermant | |
| EP0078785A1 (fr) | Sels d'acide valproîque, leur préparation et leur utilisation | |
| LU83423A1 (fr) | Pneumatique radial pour vehicules tout-terrain | |
| EP0001024B1 (fr) | Forme cristalline du sel de sodium d'un dérivé oximiné de l'acide 7-amino thiazolyl acétamido céphalosporanique, son procédé de préparation et les compositions pharmaceutiques la renfermant | |
| JP2013508272A (ja) | ブロムフェナクナトリウムの多形体、及び、ブロムフェナクナトリウム多形体の製造方法 | |
| CN101347412A (zh) | 三水合氨磷汀结晶冻干制剂及其制备方法 | |
| KR20110026311A (ko) | 엔테카비어의 신규한 염 | |
| BE686324A (cs) | ||
| FR2489318A1 (fr) | Sel d'acide((1-benzyl-1h-indazol-3-yl)oxy)acetique avec la lysine | |
| CA1181340A (fr) | Compositions pharmaceutiques renfermant des derives de l'acide 4-phenyl-4-oxo 2-butenoique | |
| TWI599571B (zh) | 伊克薩姆畢（Ｉｘａｚｏｍｉｂ）檸檬酸中間體之製造方法以及使用其製造之伊克薩姆畢檸檬酸 | |
| EP0001021A2 (fr) | Nouveaux dérivés d'alcaloides pentacycliques, procédé de préparation, application à la synthèse de produits du groupe de l'éburnamonine et compositions pharmaceutiques | |
| CA1140155A (fr) | PROCEDE DE PREPARATION D'UN NOUVEAU DERIVE DU 1.alpha.,25-DIHYDROXY CHOLECALCIFEROL | |
| CN109847067B (zh) | 一种双氯芬酸-甘氨酸-白藜芦醇偶联物、制备方法及应用 | |
| BE1001252A4 (fr) | Nouveaux derives de l'acide 4-phenyl 4-oxo 2-butenoique, leur procede de preparation, leur application comme medicaments et les compositions les renfermant. | |
| FR2481270A1 (fr) | Nouveaux derives substitues de l'acide 4-phenyl 4-oxo 2-hydroxy butanoique, procede pour leur preparation et applications comme medicaments | |
| CH641775A5 (fr) | N-(1-methyl 2-pyrrolidinyl methyl) 2,3-dimethoxy 5-methylsulfamoyl benzamide et ses derives, son procede de preparation et composition le renferment. | |
| FR2488136A1 (fr) | Composition pharmaceutique a base de salicylate d'imidazole | |
| JPS5942385A (ja) | キナゾリノン誘導体 | |
| JP3990728B2 (ja) | Ｎ−［４−オキソ−２−（１ｈ−テトラゾール−５−イル）−４ｈ−１−ベンゾピラン−８−イル］−４−（４−フェニルブトキシ）ベンズアミドの塩 | |
| EP0449722B1 (fr) | Nouveaux complexes de l'acide tiaprofénique ou de ses esters insolubles ou partiellement solubles avec les cyclodextrines ou leurs dérivés | |
| EP0022737B1 (fr) | Imines dérivées de l'amino-5 benzodioxole-1,3 utiles comme médicaments et leur préparation | |
| EP0308349B1 (fr) | Nouveau derivé de choline, son procédé de préparation et nouveaux médicaments le contenant | |
| FR2504005A2 (fr) | Application a titre de medicaments de derives substitues de l'acide 4-phenyl 4-oxo-2-butenoique | |
| LU83081A1 (fr) | Compositions antitumeurs |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| RE | Patent lapsed |
Owner name: ZAMBON S.P.A. Effective date: 19840901 |